

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Secukinumab for treating moderate to severe hidradenitis suppurativa [ID4039]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The following potential equality issues were raised during draft scope consultation:

- Incidence of hidradenitis suppurativa is higher in people of African-Caribbean family background, as compared with people of European family background
- Peak prevalence is in females of child-bearing age

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The company (Novartis) have noted that no equality issues are foreseen if secukinumab were to be recommended for use for all patients at the anticipated positioning. The potential equality issues will be fully considered by the committee during the appraisal process.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No actions required. The background section of the scope currently notes that 'The disease is more common in women than in men. People of

African-Caribbean family background have a higher incidence than people of European family background.'

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No. It is expected that the patient and carer organisations currently included on the stakeholder list will be able to provide the relevant insight into the equality issues highlighted.

Approved by Associate Director (name):

Date: [xx/xx/year]